Increased Small Intestine Expression of Non‐Heme Iron Transporters in Morbidly Obese Patients With Newly Diagnosed Type 2 Diabetes

Moreno-Navarrete, José María; Rodrı́guez, Amaia; Becerril, Sara; Valentí, Víctor; Salvador, Javier; Frühbeck, Gema; Fernández‐Real, José Manuel

doi:10.1002/mnfr.201700301

Cited by 3 publications

(2 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Obesity is one of the independent risk factors for diabetes (Moreno-Navarrete et al, 2018). A number of studies found that many intestinal iron metabolism proteins in morbidly obese patients with type 2 diabetes mellitus (T2D) were associated with glucose tolerance, such as SLC40A1, HAMP, TF, TFRC, ferritin heavy chain 1 (FTH1), ferritin light chain (FTL), and so on (Aras et al, 2021).…”

Section: Slc40a1 and Diabetesmentioning

confidence: 99%

SLC40A1 in iron metabolism, ferroptosis, and disease: A review

Zhang,

Zou,

et al. 2024

WIREs Mechanisms of Disease

View full text Add to dashboard Cite

Solute carrier family 40 member 1 (SLC40A1) plays an essential role in transporting iron from intracellular to extracellular environments. When SLC40A1 expression is abnormal, cellular iron metabolism becomes dysregulated, resulting in an overload of intracellular iron, which induces cell ferroptosis. Numerous studies have confirmed that ferroptosis is closely associated with the development of many diseases. Here, we review recent findings on SLC40A1 in ferroptosis and its association with various diseases, intending to explore new directions for research on disease pathogenesis and new therapeutic targets for prevention and treatment.This article is categorized under: Cancer > Genetics/Genomics/Epigenetics Metabolic Diseases > Molecular and Cellular Physiology

show abstract

Section: Slc40a1 and Diabetesmentioning

confidence: 99%

SLC40A1 in iron metabolism, ferroptosis, and disease: A review

Zhang,

Zou,

et al. 2024

WIREs Mechanisms of Disease

View full text Add to dashboard Cite

show abstract

“…To be specific, the serum iron level, serum ferritin level, and transferrin saturation of diabetic patients were higher than those of healthy individuals, while serum hepcidin levels were considerably lower [ 4 ]. It has been demonstrated that the expression of divalent metal transporter 1, which is vital for iron uptake in most cells, was significantly improved in the small intestine of diabetic patients [ 5 ]. Our previous results showed that different dietary iron levels had significant effects on liver glycogen deposition, blood glucose and insulin levels in db/db mice and revealed that dietary high iron levels could deteriorate the development of T2DM [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Iron Chelator Deferoxamine Alleviates Progression of Diabetic Nephropathy by Relieving Inflammation and Fibrosis in Rats

Feng,

Jia,

et al. 2023

Biomolecules

View full text Add to dashboard Cite

Diabetic nephropathy (DN) is one of the most devastating diabetic microvascular complications. It has previously been observed that iron metabolism levels are abnormal in diabetic patients. However, the mechanism by which iron metabolism levels affect DN is poorly understood. This study was designed to evaluate the role of iron-chelator deferoxamine (DFO) in the improvement of DN. Here, we established a DN rat model induced by diets high in carbohydrates and fat and streptozotocin (STZ) injection. Our data demonstrated that DFO treatment for three weeks greatly attenuated renal dysfunction as evidenced by decreased levels of urinary albumin, blood urea nitrogen, and serum creatinine, which were elevated in DN rats. Histopathological observations showed that DFO treatment improved the renal structures of DN rats and preserved podocyte integrity by preventing the decrease of transcripts of nephrin and podocin. In addition, DFO treatment reduced the overexpression of fibronectin 1, collagen I, IL-1β, NF-κB, and MCP-1 in DN rats, as well as inflammatory cell infiltrates and collagenous fibrosis. Taken together, our findings unveiled that iron chelation via DFO injection had a protective impact on DN by alleviating inflammation and fibrosis, and that it could be a potential therapeutic strategy for DN.

show abstract